Yes, methotrexate frequently causes elevated liver enzymes
Methotrexate causes elevated hepatic transaminases in approximately 49% of patients above the upper limit of normal, though these elevations are often transient and do not necessarily indicate serious liver injury. 1
Incidence and Clinical Significance
The elevation of liver enzymes with methotrexate is well-documented across multiple conditions:
In rheumatoid arthritis patients: Pooled data from 2,062 patients showed cumulative incidence of abnormal ALT/AST was 48.9% above the upper limit of normal (ULN) and 16.8% above two times ULN after a mean of 3.3 years on methotrexate 1
Gastrointestinal events and elevated liver enzymes are the most frequently encountered toxicities with long-term methotrexate use 1
In psoriasis patients: Hepatotoxicity risk is particularly high, with greater incidence than in rheumatoid arthritis patients 2, 3
The critical distinction is that most transaminase elevations are transient and asymptomatic, and do not predict subsequent serious hepatic disease 4. However, serious hepatotoxicity including fibrosis and cirrhosis can occur, typically after prolonged use (generally two years or more) and cumulative doses exceeding 1.5 grams 4.
Monitoring and Management Algorithm
When starting or increasing methotrexate dose: Monitor ALT with or without AST, creatinine, and CBC every 1-1.5 months until stable dose is reached, then every 1-3 months thereafter 1
Management based on transaminase elevation:
ALT/AST >3× ULN (confirmed): Stop methotrexate immediately. May reinstitute at lower dose following normalization 1
ALT/AST persistently elevated up to 3× ULN: Adjust methotrexate dose downward 1
Persistent elevation >3× ULN after discontinuation: Consider diagnostic procedures and evaluate for other causes including NSAIDs, obesity, alcohol, and other hepatotoxic medications 1
Risk Factors for Hepatotoxicity
Patients at higher risk for methotrexate-induced hepatotoxicity include those with 3, 2, 3:
- Obesity (particularly BMI ≥30-40 kg/m²)
- Diabetes mellitus
- Hyperlipidemia/nonalcoholic fatty liver disease
- Greater than moderate alcohol consumption
- Chronic hepatitis B or C
- Concomitant hepatotoxic medications (NSAIDs, leflunomide, retinoids, azathioprine, statins)
- Advanced age
- Renal impairment
Protective Measures
Folic acid supplementation (at least 5 mg/week) significantly reduces hepatotoxicity and should be administered to all patients on methotrexate 1. Studies show folic acid at 1 mg/day provides significant protective effect against hepatotoxicity (OR 0.17; 95% CI 0.09 to 0.32) 1.
Serious Hepatotoxicity Risk
While transaminase elevations are common, serious liver injury is rare:
- Pooled data showed mild fibrosis in 15.3%, severe fibrosis in 1.3%, and cirrhosis in 0.5% of RA patients after mean 4.1 years on methotrexate 1
- Pre-methotrexate biopsies already showed 9.1% mild fibrosis and 0.3% cirrhosis, suggesting not all liver disease is methotrexate-induced 1
- Methotrexate-induced fibrosis/cirrhosis is rare in rheumatoid arthritis patients 1
Important Caveats
Transient liver enzyme elevations immediately post-dose are expected and not cause for alarm 4. The FDA label notes these are "usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease" 4.
Persistent abnormalities warrant investigation, but single isolated elevations often normalize spontaneously 1. The key is distinguishing between benign transient elevations and persistent abnormalities that may indicate developing fibrosis.
For patients with risk factors, non-invasive liver fibrosis assessment (such as transient elastography) is recommended before starting methotrexate and annually during treatment, rather than routine liver biopsy 2.